Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00883272 · ClinicalTrials.gov registry record
Effect of DT56a (Femarelle) on the Coagulation System in the Treatment of Postmenopausal Women
A clinical trial, sponsored by NYU Langone Health.
- Completed
- Registry status
- 32
- Enrollment target
NCT00883272 is a clinical trial that has completed, run by NYU Langone Health. The registered enrollment target is 32 participants.
The verdict
NCT00883272 has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- 32 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if Femeralle (DT56a) has an effect on the coagulation system, measured by platelet adhesion and aggregation, of normal and thrombophilic postmenopausal women.
Interventions
- DIETARY_SUPPLEMENT DT56a (Femarelle) [Se-cure pharmaceuticals, Dalton, Israel]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2007-01 |
| Est. Completion | 2009-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00883272
The ClinicalTrials.gov registry entry for NCT00883272 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DT56a (Femarelle) [Se-cure pharmaceuticals, Dalton, Israel] is the first listed.
NCT00883272 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00883272 about?
NCT00883272 is a clinical study titled "Effect of DT56a (Femarelle) on the Coagulation System in the Treatment of Postmenopausal Women". The purpose of this study is to determine if Femeralle (DT56a) has an effect on the coagulation system, measured by platelet adhesion and aggregation, of normal and thrombophilic postmenopausal women.
What is the current status of trial NCT00883272?
This trial is currently completed. The enrollment target is 32 participants. The study started on 2007-01. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00883272?
The interventions under investigation include: DT56a (Femarelle) [Se-cure pharmaceuticals, Dalton, Israel] (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00883272?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.